Sensorion has announced its results for the first half of the year to June 30, 2016.
Net loss amounts to €4.3M at June 30, 2016, compared with a net loss of €1.5M at June 30, 2015.
Laurent Nguyen, CEO of Sensorion, comments: “The first half of 2016 was characterized by the intensive work undertaken by all of our teams on our drug candidates in the field of inner ear pathologies. This considerable effort resulted in substantial scientific newsflow from the start of the second half, illustrating the tangible progress made towards meeting our commitments. Our leading drug candidate, SENS-111, has a well-documented safety profile, and we are ready to assess its efficacy in acute severe vertigo during an international phase 2 clinical trial that will be carried out in the United States and Europe. The activity signals observed via the caloric test bode well for this key development stage. We have also strengthened our portfolio with a new drug candidate, SENS-401, which shows considerable potential in the treatment of inner ear lesions and could further expand our intellectual property. Lastly, we have a financial situation that will enable us to cope with the gradual ramping up of our programs.”